Stockwinners Market Radar for June 11, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:06 EDT Cathie Wood's ARK Investment buys 91K shares of PacBio today

19:47 EDT GAP Airports buys 51.5% of Guadalajara World Trade Center - The company states: "Grupo Aeroportuario del Pacifico informs that today signed the acquisition of 51.5% of the shares representing the capital stock of the company Guadalajara World Trade Center, S.A. de C.V., GWTC, for a total amount of MXN875.5M. GWTC is a group consisting of seven companies that specialize in handling, storage, and custody services for international cargo. These services are provided in facilities classified as free trade zone at Guadalajara Airport and Puebla Airport. In 2023, GWTC generated revenues above Ps. 1.0 billion, with an EBITDA margin of around 40%, and without financial debt."

18:48 EDT Coterra Energy CEO: We have an organization built for nimbleness - In an interview on CNBC's Mad Money, Tom Jorden said it's hard to look at the macro situation with natural gas and not be "deeply optimistic." There is a lot of natural gas in the U.S. ready to be brought to market and the company is well positioned to take advantage of those prospects, he noted. He expects wind and solar to be a larger part of the overall energy mix going forward.

18:34 EDT Twilio CEO sells $1.4M in common stock - In a regulatory filing, Twilio disclosed that its CEO Khozema Shipchandler sold 24.6K shares of common stock on June 7th in a total transaction size of $1.4M.

17:53 EDT Ultragenyx and Mereo announce results from Phase 2/3 Orbit study - Ultragenyx Pharmaceutical (RARE) and Mereo BioPharma Group (MREO) announced positive 14-month results from the Phase 2 portion of the ongoing Phase 2/3 Orbit study demonstrating that, as of a May 24 data cut-off date, treatment with setrusumab continued to significantly reduce incidence of fractures in patients with OI with at least 14 months of follow-up. Treatment with setrusumab also resulted in ongoing and meaningful improvements in lumbar spine bone mineral density, or BMD, at month 12 without evidence of plateau. The large reduction in annualized radiologically confirmed fracture rate previously reported in patients treated for a minimum of 6 months was sustained in patients treated for at least 14 months with a high degree of significance. The median annualized rate of radiologically confirmed fractures across all 24 patients in the 2 years prior to treatment was 0.72. Following a mean treatment duration period of 16 months, the median annualized fracture rate was reduced 67% to 0.00. The annualized fracture rate excluded morphometric vertebral fractures and fractures of the fingers, toes, skull, and face, consistent with the Phase 3 study primary efficacy endpoint. The reduction in annualized fracture rates was associated with continued, clinically meaningful increases in BMD. Tests conducted at the 12-month timepoint demonstrated that treatment with setrusumab resulted in a mean increase in lumbar spine BMD from baseline of 22% across all age groups (5 to less than 26 years old), a further improvement from 14% observed at 6 months of treatment. This increase in BMD is reflected in the change from the mean baseline lumbar spine BMD Z-score of -1.73 to -0.49 at 12 months across all age groups, a substantial normalization in Z-score of +1.25. This is further improved from the mean 6-month Z-score change of +0.85. The improvements in BMD and Z-scores were significant and consistent across all OI sub-types studied.

17:39 EDT GitLab CFO Robins sells over $508K in company shares - Gitlab CFO Brian Robins disclosed the sale of 11,667 shares of company stock on June 7 at $43.56 per share for a total transaction amount of $508,215.

17:08 EDT RadNet VP David Katz sells over $1M in company shares - VP of RadNet David Katz disclosed the sale of 16,400 shares of company stock at $61.26 per share on June 7, for a total transaction amount of $1,004,664.

16:34 EDT Greif announces 6% price boost for tube, core and protective packaging products - Greif announced it is implementing a minimum 6% increase on all tube and core and protective packaging products. The tube and core and protective packaging increase is effective with shipments on and after July 15, 2024. The tube and core and protective packaging products price increase is a consequence of the URB price increase, the primary raw material contained in those products.

16:29 EDT Artisan Partners reports May AUM $158.6B - Artisan Partners reported that its preliminary assets under management, or AUM, as of May 31 totaled $158.6B. Artisan Funds and Artisan Global Funds accounted for $77.5B of total firm AUM, while separate accounts and other AUM accounted for $81.1B.

16:20 EDT Invesco reports preliminary AUM $1.69T as of May 31 - An increase of 3.8% versus previous month-end. The firm delivered net long-term inflows of $5.2B in the month. Non-management fee earning net inflows were $5.7B and money market net inflows were $7.7B.

16:17 EDT Ready Capital announces acquisition of Madison One, no terms - Ready Capital announced that it has acquired Madison One Capital, M1 CUSO and Madison One Lender Services a leading originator and servicer in the highly profitable government guaranteed loan industry focusing on United States Department of Agriculture USDA and SBA guaranteed loan products. Terms of the transaction were not disclosed. The transaction will expand Ready Capital's presence in USDA lending through programs that support guaranteed loans for small businesses and energy projects in rural areas. The addition of Madison One, a leading USDA lender and servicer, meets Ready Capital's objective to diversify revenue sources and increase scale of gain-on-sale businesses. Ready Capital is already the fourth largest originator of SBA 7 loans to small businesses...Madison One will operate as a subsidiary of Ready Capital using its current name and brand. Madison One's entire team, led by Managing Directors Jason Bengert, Chris Balestrino and Servicing Director Lindsey Billings have joined the new subsidiary. The Madison One business line will be managed by ReadyCap Lending, reporting to Gary Taylor, ReadyCap Lending CEO.

16:16 EDT KKR makes strategic investment in Quick Quack Car Wash - KKR and Quick Quack Car Wash "announced that investment funds managed by KKR have made a significant minority investment in the Company. Quick Quack's founders and its longtime equity partner, Seidler Equity Partners, will continue to hold meaningful stakes in the Company alongside KKR. The new investment will support the continued acceleration of Quick Quack's growth through innovation, marketing and organic expansion in new and existing markets. Founded in 2004, Quick Quack is one of the largest and fastest growing express format car wash operators in the U.S., with over 230 locations across California, Texas, Arizona, Utah, and Colorado."

16:13 EDT Armlogi in strategic pact with Massimo to enhance vehicle assembly, distribution - Armlogi Holding (BTOC), a U.S.-based warehousing and logistics service provider, announced a strategic partnership with Massimo Group (MAMO), a manufacturer and distributor of powersports vehicles and pontoon boats. The goal of this collaboration will be to maximize the operational capabilities of both companies by optimizing the delivery, assembly, and distribution of vehicle components closer to their final destinations. Under the terms of the agreement, Armlogi will manage the reception of container shipments containing Massimo's vehicle kits from Asian suppliers. Armlogi will provide access to its facilities located throughout the U.S., which are equipped with technology and specialized equipment necessary for handling and storing large and bulky items, adhering to ISO 9001 industry standards. Massimo will conduct vehicle assembly within Armlogi's warehouses, while Armlogi will oversee inventory management, storage services, and the logistics required for delivering the assembled vehicles to their final order destinations across the United States.

16:10 EDT Armlogi in strategic pact with Massimo to enhance vehicle assembly and distribu - Armlogi Holding (BTOC), a U.S.-based warehousing and logistics service provider announced a strategic partnership with Massimo Group (MAMO), a manufacturer and distributor of powersports vehicles and pontoon boats. The goal of this collaboration will be to maximize the operational capabilities of both companies by optimizing the delivery, assembly, and distribution of vehicle components closer to their final destinations. Massimo Group based in Garland, TX, is a manufacturer and distributor of powersports vehicles and pontoon boats. Massimo's product lines include a wide selection of farm and ranch-tested utility terrain vehicles "UTVs, recreational all-terrain vehicles ATVs, and Americana style mini-bikes.Under the terms of the agreement, Armlogi will manage the reception of container shipments containing Massimo's vehicle kits from Asian suppliers. Armlogi will provide access to its facilities located throughout the U.S., which are equipped with technology and specialized equipment necessary for handling and storing large and bulky items, adhering to ISO 9001 industry standards. Massimo will conduct vehicle assembly within Armlogi's warehouses, while Armlogi will oversee inventory management, storage services, and the logistics required for delivering the assembled vehicles to their final order destinations across the United States.

16:08 EDT AllianceBernstein reports preliminary AUM $757B as of May 31 - AllianceBernstein announced that preliminary assets under management increased to $757B during May 2024 from $736B at the end of April. The 3% increase was driven by market appreciation and firmwide net inflows. By channel, net inflows in Retail and Institutions were partially offset by slight net outflows in Private Wealth.

16:06 EDT Oracle reports Q4 Cloud revenue $5.3B, up 20% in USD - Reports: Q4 Cloud Revenue (IaaS plus SaaS) $5.3 billion, up 20% in USD and constant currency; Q4 Cloud Infrastructure (IaaS) Revenue $2.0 billion, up 42% in USD and constant currency; Q4 Cloud Application (SaaS) Revenue $3.3 billion, up 10% in USD and constant currency; Q4 Fusion Cloud ERP (SaaS) Revenue $0.8 billion, up 14% in USD and constant currency; Q4 NetSuite Cloud ERP (SaaS) Revenue $0.8 billion, up 19% in USD and constant currency.

16:05 EDT Tevogen enters agreement for up to $50M in financing - Tevogen, following the recent elimination of $94.9M in balance sheet liabilities, has entered into a definitive agreement for up to $50M in financing. This formalizes the binding term sheet previously announced May 10. Combined with this financing, Tevogen's business model is expected to support research and development, particularly focusing on TVGN 489 the company's initial product from its ExacTcell technology platform, and to strengthen its IP portfolio. The financing consists of a combination of a $36M line of credit and a $14M contingent private placement. The line of credit is available immediately and allows Tevogen Bio to access up to $1M per month at an annual interest rate of the lower of (a) the daily SOFR plus 2.0% and (b) 7.0%, accruing quarterly and payable in common stock at an effective price of $1.50 per share. Draws can be made under the line of credit for up to 36 months. The maturity date of each draw will be four years after the draw, and principal amounts are payable in cash or in common stock. Prepayment will be permitted without penalty. The private placement is available at the counterparty's option after the trailing 10-day volume weighted average share price reaches $10 per share and would be priced at a 30% discount to that price. The private placement can also include any remaining available and undrawn amount of the line of credit.

16:04 EDT Rentokil jumps 11% to $29.95 after Bloomberg report of Trian stake

16:03 EDT Sprout Social names Erika Trautman as Chief Product Officer - Sprout Social announced the appointment of Erika Trautman to chief product officer, effective July 15. As chief product officer, Trautman will oversee Sprout's global product organization and focus on elevating and expanding Sprout's innovative product offering. Trautman brings more than 15 years of experience in technology to Sprout with a career that has spanned work as a start-up founder to the management of billion-user products. Prior to Sprout, Trautman was the senior vice president and general manager of the work management portfolio at Atlassian, where she was responsible for driving hundreds of millions in revenue for the company through industry-leading product and AI strategy. Trautman also previously held the role of product director at Google, where she helped achieve broad adoption and significant year-over-year revenue growth for Google Drive and Editors as the company navigated exponential demand to scale during the pandemic. Additionally, she reinvigorated end-user innovation for the Google Editors suite of collaboration tools and implemented machine learning initiatives across the portfolio.

16:02 EDT Origin Materials regains compliance with Nasdaq listing requirements - Origin Materials announced that on June 11, 2024 it received written notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market stating that the company regained compliance with the Minimum Bid Price Requirement set forth in Nasdaq Listing Rule 5550(a)(2). The company had previously been notified by the Nasdaq on January 4, 2024, that it was not in compliance with the Minimum Bid Price Requirement, as the closing bid price of the company's common stock had been below $1.00 for more than 30 consecutive business days. In order to regain compliance with the Minimum Bid Price Requirement, the company was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days, which was achieved on June 10, 2024.

15:42 EDT Paramount down 8% after WSJ says National Amusements stops talks with Skydance - Shares of Paramount Global are down 90c, or 8%, to $11.07 after The Journal's report about its controlling shareholder stopping discussions with Skydance.

15:00 EDT Celsius CEO says Celsius growing, energy drink category 'slowing' - Asked while presenting at the Evercore ISI Consumer and Retail Conference about recent scanner data that shows the energy drink sector overall has slowed, Celsius Chief Executive Officer John Fieldly replied, according to a transcript of the event: I mean, the category has been slowing, Robert. You're absolutely right. I mean, it's we're watching it very closely over the last several weeks. You know, there's a lot of forecasts as well that, you know, still anticipating good growth in the category. So we're kind of waiting for that to turn around here. You know, we're heading into summer right now. It's the busiest beverage season that, you know, when you look at July, August, you know, usually best months of the year. So those are things that we're waiting on. I think the little we've have been disappointed with the category not seeing that category growth as we anticipated. But, you know, there seems to be a lot of factors from seeing a lot of the write ups on weather and timing of resets. And it could be also, you know, the spending patterns on, you know, consumers starting to feel the pinch on the gas pump and all the rising costs. So there's a lot of variables there I think you look at total beverage overall and it's, you know, be interesting to see the reports coming out, but you're starting to see some spending, deep spending, deep cuts, you know, that you haven't seen over. I think when you look at, you know, Celsius specifically, you know, we're showing good growth as well on the, you know, the scanner data. So Celsius is growing. I think if you back out Celsius out of the energy drink category, it's, you know, in a negative position on growth."

14:41 EDT NextEra Energy under pressure following 2027 guidance - Shares of NextEra Energy are under pressure on Tuesday after the company reaffirmed its adjusted EPS outlook through 2026 and guided 2027 adjusted EPS between $3.85-$4.32 a share. NextEra says it expects adjusted earnings to grow at a 13% CAGR from 2023 to 2027, and adjusted EBITDA to grow at a 16% CAGR from 2023 to 2027. Shares of NextEra Energy have dropped over 6% to $72.05 in afternoon trading.

13:14 EDT Massachusetts AG announces $700M Johnson & Johnson talc settlement - Massachusetts Attorney General Andrea Joy Campbell and 42 other attorneys general have reached a $700M nationwide settlement, via a proposed consent judgment filed today in Suffolk Superior Court, with Johnson & Johnson to resolve allegations related to the marketing of Johnson & Johnson's talc-containing baby powder and body powder products. Massachusetts is set to receive approximately $14.5M through 2027 as part of the multistate consent judgment, which is pending judicial approval, the AG stated. Reference Link

12:19 EDT Origin Life Sciences to present on devices for treatment of battlefield wounds - Origin Life Sciences announced that the Company's abstract, titled: "NO: a Novel, Pathogen-Agnostic Therapy for Treatment-Resistant Wound Infections in the Warfighter," has been accepted for presentation at 2024 Military Health System Research Symposium. MHSRS, America's foremost annual military-healthcare conference, is scheduled from 26-29 August 2024 at the Gaylord Palms Resort and Convention Center, Kissimmee, FL. The abstract was accepted under the breakout session: Innovative Technologies and Devices for Treatment of Battlefield Wounds in Prolonged Care to Prevent Infection. The poster for this breakout session will be presented in Poster Session 3 on Wednesday, August 28, 2024 by Dr. Terry Treadwell, Vice President of the Wound and Lymphedema committee of the World Health Organization and the Company's Chief Clinical Officer designate. Key aspects of the abstract, include: Introduction: Nitric oxide, produced by white blood cells and macrophages, is key to the body's defense against bacteria, viruses, fungi, and parasites. Capability: Although active in vitro against these pathogens, NO has not before been useful in clinical treatments due to its short half-life and inability to penetrate tissue. A newly-developed, clinically-proven technology - in which NO is produced from room air in a stream of high-energy plasma - has shown promise in treating infected wounds without challenges associated with antimicrobial resistance. In this form, NO has an increased half-life and the ability to penetrate tissue. The treatment is easy to give, non-invasive, and has a favorable safety profile. In greater than1,000 treatments given to patients with complex wounds in FDA trials, there were no device-related adverse effects. Methods/Technical Approach: The plasma energy stream is delivered to the wound and surrounding tissue for between 5 and 10 minutes. The field-adaptable machine does not touch the patient, and only standard electrical power is needed to produce the plasma energy/NO. Results: This device has been shown to significantly improves the healing of traumatic wounds that have resisted standard forms of care. Applicability to Medical Roles of Care: Plasma energy/NO kills organisms by mechanisms which prevent them from developing resistance. Since it is pathogen-agnostic, microbe-identification is not needed before treatment. Plasma energy enables the NO to penetrate the skin and tissue for greater than3 cm into the affected site. The stream is believed to increase microcirculation, stimulate hemostasis, promote tissue-regeneration and stem cell activation, and modulate the immune system. Its potential anti-inflammatory effect may be able to reduce edema and pain. The device's mobility in its portable form and its ease of use are ideal in the field where resources are limited. Field-adapted versions have been deployed to the field and successfully treated patients. Early treatment can prevent wound infections, treat contaminated wounds, and accelerate healing, without concern for AMR. Where care is provided, the therapy will lead to infection control, faster wound healing, and control of pain and inflammation. Impact to the Warfighter: This field-capable device has the potential to treat infected and uninfected wounds, is pathogen agnostic, avoids antibiotic resistance, and we believe has other benefits that accelerate wound healing. Developmental Status: The technology is in use in clinical trials under FDA and independent IRBs.

12:05 EDT Onity Group falls -7.6% - Onity Group is down -7.6%, or -$1.84 to $22.51.

12:03 EDT CoreCivic falls -20.0% - CoreCivic is down -20.0%, or -$2.96 to $11.83.

12:01 EDT GCT Semiconductor rises 9.3% - GCT Semiconductor is up 9.3%, or 33c to $3.86.

12:00 EDT Yatsen rises 12.8% - Yatsen is up 12.8%, or 36c to $3.23.

11:50 EDT General Motors lowers 2024 EV sales forecast to 100,000-150,000 - General Motors Chief Financial Officer Paul Jacobson said at a Deutsche Bank conference that the company now expects 2024 electric vehicle sales of 100,000 to 150,000, down from the company's previously announced range of 200,000 to 300,000 units. "So at the lower end of that, and I think it reflects the momentum that we have in the business," Jacobson said.

11:14 EDT Boeing reports 4 airplane gross orders, 24 commercial deliveries in May - In its commercial aircraft operations, Boeing reports 4 airplane gross orders and 24 commercial deliveries in May, according to data posted to its corporate website. Boeing reports 130 year-to-date net orders, 103 year-to-date orders net of cancellations/conversions and 6,188 unfilled airplane orders as of May 31, 2024. Reference Link

10:53 EDT NetApp sees double-digit EPS growth on average over FY25-FY27 - In slides for its investor day detailing the company's three-year financial model, NetApp says it targets mid-to-upper single digit revenue growth on average for FY25-FY27, an operating margin greater than 30% by FY27 and double-digit EPS growth on average for FY25-FY27.

10:37 EDT Arena Group files lawsuit against ABG, Minute Media for theft of technology - The Arena Group has filed a lawsuit against ABG, who own the rights to Sports Illustrated, and against Minute Media, for theft of Arena's technology. The company said, "The lawsuit highlights how ABG conspired to steal the crown jewel of Arena's business - the proprietary code technology and trade secrets comprising the valuable internet platform Arena developed at a significant expense...The suit showcases that ABG enlisted business leaders from top tier investment firms - including CVC Capital Partners and BlackRock - to help steal proprietary technology and business from Arena, working with ABG's new licensee, Minute, to orchestrate a multi-step corporate heist...Arena also notes that ABG has a history of monopolistic and predatory licensing behavior. The lawsuit highlights how Arena is 'just the latest licensee to fall victim to ABG's extensive and public history of strip-mining its license partners, imposing steep guaranteed royalties and termination fees that award ABG a windfall.' Another company, 888 Holdings, was forced to terminate its unprofitable joint venture with ABG earlier this year, triggering an oppressive $50 million termination fee. Arena strongly believes that ABG's theft and predatory practices, along with those of their accomplice Minute, who greatly benefited from Arena's years of research, development, and implementation, will be made clear in a court of law." Arena seeks $200 million in damages. The case is pending in federal court in the Southern District of New York.

10:33 EDT Redwoods Acquisition Corp trading halted, volatility trading pause

10:21 EDT GameStop trading resumes

10:05 EDT ZIM Integrated falls -12.6% - ZIM Integrated is down -12.6%, or -$2.58 to $17.96.

10:03 EDT Cboe Global Markets expands collaboration with FTSE Russell - Cboe Global Markets announced it is expanding its collaboration with FTSE Russell. This new initiative builds on Cboe and FTSE Russell's longstanding relationship and will leverage their combined expertise to develop new derivatives products, potentially beginning with cash-settled index options tied to the FTSE Bitcoin Index and the FTSE Ethereum Index. The collaboration underscores the companies' shared commitment to growing the digital assets space and expanding investor access to the asset class. Cboe's plans to list cash-settled index options on FTSE's indices, subject to regulatory approvals, would help meet growing investor demand for exchange-traded derivatives to gain and manage crypto exposures in a trusted, transparent and U.S.-regulated trading environment.

10:02 EDT VF Corp. rises 4.2% - VF Corp. is up 4.2%, or 55c to $13.71.

10:01 EDT Net Lease Office rises 5.5% - Net Lease Office is up 5.5%, or $1.28 to $24.54.

09:55 EDT NetApp reports hiring Mike Sakalas as Vice President of U.S. Enterprise Sales - Earlier, NetApp (NTAP) announced hiring Mike Sakalas as the company's Vice President of U.S. Enterprise Sales. Sakalas will report to NetApp's Senior Vice President of North America Sales, Riccardo Di Blasio. Prior to joining NetApp, he served as the Vice President of Enterprise and U.S. Global Sales at Pure Storage (PSTG), where he also previously led sales for its Australia and New Zealand regions, the company noted.

09:51 EDT Yext falls -11.1% - Yext is down -11.1%, or -56c to $4.48.

09:49 EDT VF Corp. rises 3.8% - VF Corp. is up 3.8%, or 50c to $13.66.

09:47 EDT Desktop Metal rises 6.9% - Desktop Metal is up 6.9%, or 34c to $5.25.

09:34 EDT Culper Research short Axsome Therapeutics, sees shares 'headed lower' - In a recently published report, Culper Research said it is short Axsome Therapeutics and sees shares "headed lower" as it believes the company's "launch of Auvelity for major depressive disorder has been aided by undisclosed consignment deals with dodgy mail-order pharmacies that subvert prior authorizations, inflating script counts and reported revenues." "In short, Axsome has simply not been paid for 43% of its reported Auvelity revenues since launch. Tellingly, Axsome dismissed its longtime auditor E&Y in June 2023, and in both of its past two annual reports, the Company disclosed critical audit matters related to revenue recognition," the report reads. "We believe that to avoid this burden of PAs at standard pharmacies, Axsome has engaged in an undisclosed program that both consigns Auvelity to a network of dodgy mail-order pharmacies then steers prescriptions towards those pharmacies. These pharmacies then use Axsome's copay cards to fill Auvelity prescriptions prior to even submitting the claim to payors, let alone obtaining an approved PA. This raises anti-kickback concerns, false claims concerns, and revenue recognition concerns, in our view." Shares of Axsome have dropped about 8% to $66.01 in morning trading.Reference Link

09:32 EDT Caravelle regains compliance with minimum bid price requirement - Caravelle International Group received the determination letter on June 10 from Nasdaq that for the 17 consecutive business days, from May 15, 2024, to June 7, 2024, the closing bid price of the Company's ordinary shares has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with the Minimum Bid Requirement and this matter is now closed. On June 10, 2024, Nasdaq also notified the Company that, after its review of the materials provided by the Company on May 24, 2024, Nasdaq determined to grant the Company an exception to file its annual report on Form 20-F for the fiscal year ended October 31, 2023 by September 10, 2024, to enable the Company to regain compliance with Nasdaq Listing Rule 5250(c)(1). Caravelle International Group is committed to making every effort to ensure the timely submission of the annual report. This demonstrates the company's dedication to fulfilling its regulatory obligations and maintaining its listing status on the Nasdaq stock exchange.

09:27 EDT JinkoSolar module reaches record conversion efficiency of 25.42% - JinkoSolar announced a breakthrough in its N-type TOPCon solar module. Tested by TundefinedV SundefinedD, the conversion efficiency for 2 m2 above large-size solar modules has reached 25.42%, setting a new record. The module incorporates a series of technological and material innovations based on N-type TOPCon solar cells, including metalization enhancement technology, non-destructive patterning technology, and high energy density hydrogen passivation technology. The lab result has the practical foundation to be fast introduced into mass production, and technically set the direction for mass production of subsequent advanced products.

09:17 EDT Mullen Automotive announces Massachusetts issues MOR-EV approval - Mullen Automotive announced the Massachusetts Executive Office of Energy and Environmental Affairs' Department of Energy Resources as approved the Company's all-electric Class 3 low cab forward truck, the 2024 Mullen THREE, for up to a $15,000 state cash rebate voucher. Managed by the Executive Office of Energy and Environmental Affairs' Department of Energy Resources and administered statewide by the Center for Sustainable Energy,the MOR-EV program is dedicated to making electric vehicles more affordable for Massachusetts residents, businesses and non-profit organizations to help achieve clean transportation goals, reduce greenhouse gas emissions and provide more equitable access to EVs. The MOR-EV Trucks program incentivizes purchases and leases of a variety of medium- and heavy-duty battery electric and fuel cell electric trucks, buses and vans. Rebates apply to both individual and fleet acquisitions. Under MOR-EV, the 2024 Mullen THREE EV truck, with a suggested MSRP of $68,500, now qualifies for up to a $15,000 cash rebate voucher. When combined with the available $7,500 federal tax credit, the net effective price of the Mullen THREE would be approximately $46,000.

09:09 EDT Pioneer Power gets $7.1M order for 25 e-Boost Mobile units for ESB fleet - Pioneer Power Solutions announced that it has received an order from one of the largest public school districts in the United States for 25 e-Boost Mobile units to power the school district's electric school bus ESB fleet. The order, valued at $7.1 M , is likely to grow to more than $8M with the expected addition of planned contingency measures. The Company plans to deliver the systems throughout the first quarter of 2025. The systems will support the school district's efforts to meet local environmental requirements by phasing out traditional fuel sources at the school bus depot and expediting the transition to a fully ESB fleet. The initial deployment will serve approximately 200 EV buses, advancing the district's goal of electrifying its fleet of more than 1,000 ESBs. As one of the largest school districts in the country, it currently operates a vast fleet of more than 3,000 vehicles, including buses, trucks, cars and vans. The receipt of this order, combined with the current backlog for Q1, positions the Pioneer eMobility business unit for significant growth in 2025, exceeding its expected 2024 performance. To support this expansion, the business unit will form strategic, geographically aligned partnerships with national manufacturing firms, thereby increasing production capacity and enabling Pioneer to meet growing demand while avoiding costly facility expansions and potential production delays or disruptions. This approach aligns with Pioneer's overall goals to grow its eMobility business efficiently, invest in sustainable solutions and drive innovation, further solidifying its commitment to a greener future.

09:07 EDT Outbrain appoints Greg Archibald as GM, SVP of sales, U.S. - Outbrain announced the appointment of Greg Archibald as General Manager & Senior Vice President of Sales for the United States. In this role, Archibald will oversee all agency and brand demand functions in the US, with a focus on driving revenue, adoption, and retention of Outbrain's high-impact performance advertising solutions, including the open internet branding platform, Onyx by Outbrain. Prior to joining Outbrain, Archibald served as Senior Vice President of Americas Media for InMobi, where he led revenue operations for the region.

09:05 EDT Euronet announces appointment of Herrero to board of directors - Euronet announced the appointment of Sergi Herrero to the Euronet Board of Directors effective June 4, 2024. His appointment increases the size of the board from nine to ten members. "We are extremely pleased to welcome Sergi to our board," said Michael Brown, Euronet's Chairman and Chief Executive Officer. "He has extensive C-level experience as an executive officer in the payment and technology industries, which, along with his experience serving the boards of fintech companies in Europe, will support Euronet as we continue to expand our business."

09:04 EDT Sage launches Sage Distribution and Manufacturing Operations in U.S. - Sage launches Sage Distribution and Manufacturing Operations in the United States and South Africa. SDMO provides complete visibility and control of the purchasing, production, inventory, and sales processes of small to mid-sized distributors and discrete manufacturers, helping them drive efficiency, productivity, and growth. SDMO is designed specifically for the manufacturing and distribution sectors and uses cloud-native technology to provide a single dedicated place to manage operations and financials. It helps organizations automate and smoothly manage complex tasks using modern capabilities such as real-time materials resource planning, dynamic work orders and digital calendars. SDMO provides organizations with the adaptability and agility they need to quickly plan for and respond to changes in demand and supply due to market volatility and supply chain issues. By embedding industry best practices, advanced multi-site inventory management, and powerful reporting with industry-specific KPIs and dashboards, SDMO helps reduce the noise, enabling companies to better understand where to prioritize resources and support.

09:04 EDT Scilex announces pharmacy chains, independent pharmacies stocking GLOPERBA - Scilex Holding announced that many national pharmacy chains and independent pharmacy stores have begun stocking GLOPERBA Scilex launched GLOPERBA, an FDA-approved prophylactic treatment for painful gout flares in adults in the U.S., on June 10, 2024

09:03 EDT Model N introduces two new integrated data solutions - Model N unveiled two new integrated data solutions that address critical business needs for life sciences manufacturers. Syndicated Customer Master and Formulary Compliance were designed in close partnership with the world's leading life sciences companies to address pressing industry challenges with significant business impact. "Model N's new integrated data solutions, Syndicated Customer Master and Formulary Compliance, directly address the need for data integrity and contract adherence for today's leading life sciences manufacturers," said Suresh Kannan, Chief Product Officer at Model N. "Disparate master data sets and inaccurate formulary positions are common reasons for lost revenue among life sciences manufacturers, which our two new solutions address head-on."

09:02 EDT Longeveron announces completion of investigator meeting for ELPIS II - Longeveron announced the successful completion of an investigator meeting for ELPIS II, the on-going Phase 2b clinical trial evaluating Lomecel-B as a potential adjunct treatment for Hypoplastic Left Heart Syndrome, HLHS, a rare pediatric congenital heart birth defect. The investigator meeting was organized to discuss the progress to date and operational implementation of the clinical trial, inviting the principal investigator and site staff from premiere infant and children's treatment institutions across the country. ELPIS II is on track to complete enrollment by the end of 2024.

09:01 EDT Check Point announces CloudGuard WAF-as-a-Service - Check Point Software announced CloudGuard WAF-as-a-Service, an automated, AI-powered, web application firewall, that offers organizations a fully managed solution to prevent cyber threats and protect web applications from unauthorized access and data breaches. Prioritizing prevention, simplicity and scalability, this technology delivers a convenient and cost-effective way to efficiently secure cloud applications and APIs.

08:57 EDT ECD Automotive Design launches Shawnee Commission Jaguar E-type Coupe - ECD Auto announced the launch of the Shawnee Commission, a stunning ECD bespoke classic Jaguar E-Type. This one-of-a-kind creation is a meticulously restored and customized Jaguar E-Type Series III Coupe, combining timeless elegance with modern performance, luxury, and unique features.

08:54 EDT BioLargo manufactures first Cellinity battery cells - BioLargo succeeded in manufacturing its first Cellinity "Liquid Sodium" prototype battery cells.C ellinity is BioLargo's next-generation battery platform designed to provide safe, environmentally conscious large-format long-duration battery energy storage for applications including grid-scale storage, renewable energy storage, charging stations for electric vehicles, and a variety of other commercial and industrial applications. Cellinity is not a lithium-ion battery - rather, it uses a unique chemistry involving molten salt electrolytes that imparts substantial benefits over lithium-ion chemistry

08:43 EDT Nuvei acquisition by Advent recommended by Glass Lewis - Nuvei announced that proxy advisory firm Glass Lewis has recommended that Nuvei shareholders vote for the statutory plan of arrangement involving the company and Neon Maple Purchaser, a newly-formed entity controlled by Advent. The purchaser will acquire all the issued and outstanding subordinate voting shares and multiple voting shares of the company for a price of $34.00 cash per share. The special meeting of shareholders will be held on June 18. Glass Lewis is the second independent proxy advisory firm to recommend shareholders vote for the arrangement, following the recommendation from ISS. The board of directors has concluded that the arrangement is in the best interests of the company and its shareholders.

08:41 EDT Emerita provides results for Phase I metallurgical testing program at IBW - Emerita Resources provided an update on the metallurgical testing program on its wholly-owned Iberian Belt West Project. Emerita Resources has conducted Metallurgical testing Phase I, in collaboration with Wardell Armstrong International and SRK Consulting. The goal of the Phase I Program was to demonstrate that commercial grade concentrates can be produced from the Project's La Romanera and La Infanta deposits which comprise the NI 43-101 mineral resource estimate to date, and at recoveries which are potentially economic and provide required data for planned mill plant design. IBW hosts three massive sulphide deposits: La Infanta, La Romanera and El Cura. Phase I metallurgical Testing was carried out on La Romanera and La Infanta deposits. El Cura deposit is presently being drilled and will be subject to test work once the mineral resource estimate there is established. Phase I focused on the production of separate copper, lead and zinc concentrates through a sequential test methodology. As part of Phase I, the distribution of gold and silver within the various test products have been tracked however, specific gold and silver recovery testing was not the focus in this phase, still data from Phase I provides important insights with respect to optimizing the precious metals. In Phase I the precious metal recoveries were up to 48.6 % silver and 17.2 % gold in different products. Phase II, which has now been initiated, will investigate optimizing gold and silver recoveries as gravitational and/or concentrate products to bring that up to a target of 60% recovery or more. Phase I demonstrates that the IBW Project shows excellent averages, 85.6% Zinc recovery, 62% Copper recovery and 59% Lead recovery, obtaining commercial grade concentrates from both deposits. These results, which have been normalised based upon resource head grades, are in line with, and in fact, exceed the metallurgical performance of polymetallic ores presently in production in the Iberian Belt. Copper recoveries improve in areas of the deposit with higher copper grades.Emerita Resources has initiated a Phase II of the Program in collaboration with Wardell Armstrong International with two main objectives: A. To ratify the experimental data obtained in Phase I, by means of closed-circuit flotation tests following the scheme obtained in Phase I, using new average samples from each of the deposits and their possible mixtures during the LOM. B. Increase gold recoveries at La Romanera deposit by focusing on 2 basic strategies. Determine the geochemical conditions that allow the existence of free gold forming Electrum, as observed in several petrographic analysis samples. Concentrate gold by differential Pyrite/Arsenopyrite flotation on the Romanera flotation tailings.

08:39 EDT Bigg Digital Assets, WhiteStream Intelligence launch simulator training - BIGG Digital Assets announces the launch of a Cutting-Edge Operational Simulator Training for Investigators in partnership with WhiteStream Blockchain Intelligence. This innovative training solution is designed to equip law enforcement and financial crime investigators with the skills and knowledge necessary to tackle the complexities of blockchain-related crimes.

08:39 EDT Ono Pharmaceutical reports results of Deciphera acquisition - Ono Pharmaceutical (OPHLY) has successfully completed the tender offer to acquire all outstanding shares of common stock of Deciphera Pharmaceuticals (DCPH) for $25.60 per share - total amount of approximately $2.4B -, through its wholly owned subsidiary, Topaz Merger Sub. On June 11, following the completion of the tender offer, Merger Sub merged with and into Deciphera with Deciphera continuing as the surviving corporation and a wholly owned subsidiary of Ono. In connection with the acquisition, Deciphera shares ceased to be traded on Nasdaq as of the date of closing of the acquisition and shares of Deciphera's common stock will be delisted from Nasdaq.

08:37 EDT Airship AI announces six-figure sole-source contract award within DOJ - Airship AI Holdings has been awarded a large base year plus four option year contract to an agency within the Department of Justice, DOJ, for the Company's Acropolis Enterprise Sensor Management video and data management platform supporting emerging public safety and investigative requirements. "This award represents a substantial expansion of an existing deployment of our Acropolis eco-system, validating our ability to scale in size and scope as the agencies requirements grow," said Paul Allen, President of Airship AI. "Equally as exciting is the customer will be leveraging work done by other agencies within the DOJ and Department of Homeland Security to migrate from existing on-premises operations to a FedRAMP certified cloud environment, a government-wide program that provides a standardized approach to security assessment, authorization, and continuous monitoring for cloud products and services."

08:36 EDT Diana Shipping to participate in a series of fixed income investor calls - Diana Shipping will participate in a series of fixed income investor calls to be arranged. Subject to, inter alia, market conditions, a USD denominated senior unsecured bond issue with a five-year tenor may follow. The proceeds from the potential bond issue will be used to prepay in full the Company's existing $125M senior unsecured bonds with maturity in June 2026 and the balance will be used for general corporate purposes. Subject to the successful placement of the new contemplated bond issue, the Company intends to call the existing bond.

08:34 EDT Clean Energy Technologies affiliate selected as USDA grant recipient - Clean Energy Technologies announced that Vermont Renewable Gas, an affiliate of CETY in which CETY indirectly retains 49% ownership interest, has been selected by the United States Department of Agriculture as one of 171 Wood Innovations Grant recipients. Administered by the USDA's U.S. Forest Service, this $74 million initiative is made possible in part by the bipartisan Infrastructure Law and the Inflation Reduction Act. VRG was selected to receive $300,000 towards installation and testing of CETY's high temperature ablative fast pyrolysis reactor at VRG's planned facility in Lyndonville, Vermont. This grant will also support an operator training program at the facility. VRG and 170 other Wood Innovations Grant recipients were selected based on their ability to spark innovation, create new markets, and support renewable energy. Centered around CETY's HTAP Biomass Reactor technology, CETY will design, build, and operate the VRG - Lyndon facility. VRG will convert waste biomass from Northeastern Vermont's working lands into renewable fuel gas and BioChar fertilizer as a byproduct. The renewable fuel gas generated will be converted into renewable electricity and heat. The plant is expected to deliver in excess of 18,000 MWh of renewable electricity and 1,500 tons of BioChar annually and be fully commissioned within 12 months.

08:33 EDT Actinium Pharmaceuticals reports results of Actimab combination in leukemia - Actinium Pharmaceuticals highlighted data from the completed Phase 1b combination trial of Actimab-A + CLAG-M in patients with relapsed or refractory acute myeloid leukemia - r/r AML - at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting June 8 - 11 in Toronto. Actimab-A has been studied as a single agent and in combination with chemotherapies and targeted therapies in Phase 1 and Phase 2 trials. Despite the high-risk profile of the patients on the study, the combination of Actimab-A + CLAG-M produced high rates of response and measurable residual disease negativity and improved survival outcomes across all patient subsets: across all dose levels, radiation doses for key organs were well below known tolerance levels with external beam radiation ; no safety signals for major organs such as liver, heart, kidneys, lungs and intestines were observed and a safety profile consistent with that expected in heavily pre-treated r/r AML patients given salvage therapy; a single 30-minute administration of Actimab-A results in rapid radiation delivery and clearance with peak concentration reached around 0.6 hours and undetectable in the blood by 48 hours after administration; the dose of 0.75 microCi/kg was identified as optimal for this combination therapy and will be further evaluated in the next stage of clinical development.

08:32 EDT Massimo partners with Armlogi for vehicle assembly locations - Massimo Group (MAMO) announced a strategic partnership agreement with Armlogi Holding Corp (BTOC) to provide access to Armlogi warehousing facilities and tailored logistics services for fast order fulfillment of UTVS, ATVs, Go-Karts and Golf Carts. Under the agreement, Armlogi will receive containers of Massimo vehicle kits arriving from Asian suppliers at its warehouses in Savannah, GA, Edison, NJ, and Walnut, CA. Massimo will provide vehicle assembly at the warehouses, and Armlogi will supply inventory management, storage services, logistics, and delivery to final order destinations. Armlogi warehouses are equipped with advanced technology and specialized equipment to handle large and bulky items at the safest ISO 9001 industry standards.

08:27 EDT OLB Group CEO says management 'fully engaged in the success of the company' - The OLB Group issued an open Letter to Shareholders from Chairman and CEO of OLB Group, Ronny Yakov, which read in part, "Starting on a positive note, our revenues going forward will reflect business from the recent acquisition of the bodegas/convenience store network portal, Black011.com, and the mobile brands Blackwireless.com and Mangomobile.com. OLB recently acquired the remaining 19.9% equity interest of Cuentas SDI, LLC and now owns 100% of Black011.com, which will be restructured and rebranded with additional OLB products and services. Currently we service 1,800 bodegas currently and expanding month to month. Starting by the end of the Third Quarter, we will be offering a variety of new products and services, pre-paid phone cards and credit cards to the owners of bodegas and convenience stores to their underbanked and unbanked customers. Additionally, we are launching the Affordable Connectivity Program program that offers subsidies to low-income customers. We also expect to launch additional services for point of banking and bill payments in early 2025. Merchant payment services continues to be our core business and the primary business related to our custom-developed applications, which remains our strongest competitive advantage. ..On April 19, 2024, we confidentially filed an updated registration statement and a response to SEC comments on prior versions of the registration statement relating to the spin-off DMint, Inc., our Bitcoin mining subsidiary. We anticipate a clearer picture of the pending record date and spin-off date in the coming weeks, at which point, the Company will be announcing a Shareholder of Record date for the DMint stock dividend to OLB shareholders. In anticipation of the spin-off of DMint, we will be reporting in our quarterly financial statements for the six months ended June 30, 2024, DMint's underlying business as a Divested Asset, and the Liabilities of DMint on the balance sheet of OLB will be written off when we distribute shares of DMint to OLB shareholders. We are resubmitting the S-1 this week to address the remaining questions to the SEC. Despite the revenues loss resulting from the termination of merchant services of the acquired portfolio, which we have fully written off, the company projects a revenue run rate of at least $15 million for fiscal 2024. We have taken a conservative approach to the merchant portfolio acquired from FFS Data in 2021. In light of the ongoing fraud claims against FFS Data, we have made the decision to write off the FFS Portfolio and anticipate the recovery of our entire investment upon conclusion of the litigation. We are suing to reverse the transaction and seek the return of the Company's $16 million investment, all legal fees, loss of business opportunity and reputational damages...The management at OLB Group is fully engaged in the success of the company, continues to periodically buy shares at the open market and financially support the company. Today the company has no long-term liability. In conclusion, we believe that after the spinoff of DMint, OLB Group will attract analyst research coverage for both entities as separate, pure play companies engaged in Bitcoin mining and merchant services respectively."

08:22 EDT Palella Holdings acquires 51% stake in micromobility's common stock - Micromobility is pleased to announce a strategic acquisition by Palella Holdings . On June 10 Palella Holdings acquired 51% of micromobility.com Inc.'s common stock, traded on the OTC pink sheets. This acquisition involved converting $705,441.98 of the principal amount of a convertible note issued by micromobility.com Inc. on January 31, . This conversion resulted in the issuance of 47,029,465 shares of common stock to Palella Holdings at a conversion price of 1.5c per share, which was one tenth of a cent above the closing price of MCOM common stock on June 10, 2024. Palella Holdings is a related party as it is controlled by our Chief Executive Officer. micromobility.com Inc. is committed to working closely with Palella Holdings o foster growth, enhance operational efficiencies, and drive long-term value for all stakeholders.

08:21 EDT Processa announces results from preliminary eval of Phase 1b trial with NGC-Cap - Processa Pharmaceuticals announced positive efficacy results from the preliminary evaluation of its recently completed Phase 1b clinical trial which defined the Maximum Tolerated Dose, MTD, and Recommended Phase 2 Dose Range, RP2DR, for Next Generation Capecitabine, NGC-Cap, administered to patients with Stage III or IV gastrointestinal tract cancer. Key Efficacy Findings from Preliminary Analysis of NGC-Cap Phase 1b Clinical Trial: In all evaluable patients receiving one dose of PCS6422 and seven days of capecitabine, PR or SD was observed in 66.7% of evaluable patients, including two with PR and six with SD. The length of PFS was approximately 5 to 11 months across these patients. At the MTD of 225 mg of capecitabine dosed twice daily after a single dose of PCS6422, all three evaluable patients had PFS with the time to progression being approximately 5 to 7 months. At the second highest dose of 150 mg capecitabine dosed twice daily after a single dose of PCS6422, 66.7% of evaluable patients had SD with the time to progression of approximately 3 to 7 months. These two dosage regimens will be further evaluated in the Phase 2 trial in breast cancer patients to determine the optimal dosage regimen for the pivotal trial. By comparison, in the capecitabine product label, 301 metastatic colorectal cancer patients treated with monotherapy capecitabine had an overall response rate of approximately 21% and the time to progression of approximately 4.5 months.

08:20 EDT Occidental Low Carbon, TAE Technologies explore fusion energy - Oxy Low Carbon Ventures, a subsidiary of Occidental, and TAE Technologies announced they have signed a memorandum of understanding to explore commercial opportunities that use TAE's fusion technology to provide emissions-free power and heat for Direct Air Capture facilities. Through the agreement, TAE Technologies can explore demonstrating the reliability, cost savings and safety of their TAE Power Solutions power management systems in a high utilization commercial setting. "Collaborating with TAE Technologies is an opportunity to build on Occidental's portfolio of clean power sources that can provide our Direct Air Capture facilities with reliable, emissions-free energy," said Frank Koller, Vice President, Power Development, Oxy Low Carbon Ventures. "Fusion is a promising technology that advances our efforts to explore sustainable energy sources as we progress with commercializing large scale Direct Air Capture as a critical climate solution."

08:19 EDT WisdomTree reports $577M of net inflows generated in May - WisdomTree released monthly metrics for May 2024, including assets under management AUM and flow data by asset class. Monthly Commentary: WisdomTree generated $577M of net inflows in May, including positive flows into 6 of our 8 major product categories and generally into funds with fees greater than our overall blended fee rate WisdomTree's U.S. listed ETFs and offshore UCITS ETF suite generated a combined $953M of net inflows during the month and have gathered nearly $3.8B of net inflows year-to-date in 2024

08:17 EDT Annovis' buntanetap found safe, effective in high-risk Alzheimer's patients - Annovis Bio announces that its recent Phase II/III Alzheimer's study of its lead drug candidate, Buntanetap, showed statistically significant efficacy and safety in both carriers and non-carriers of Apolipoprotein E4, a genetic cause of AD. Key Findings: Efficacy in Early AD Patients: In patients with early AD (MMSE 21-24), Buntanetap showed a statistically significant dose-response in ADAS-Cog11 scores, with a -3.3 points improvement over baseline and -2.3 points improvement from placebo. APOE4 Carriers: In APOE4 carriers treated with 15mg Buntanetap, there was a -3.15 improvement in ADAS-Cog11 scores. Comparable Safety: Buntanetap was found to be equally safe in both APOE4 carriers and non-carriers, with no instances of ARIA. Patient Breakdown: The study included 159 APOE4 carriers and 159 APOE4 non-carriers.

08:16 EDT Comscore announces expansion of partnership with Anzu - Comscore announced an expansion of its partnership with Anzu for the most advanced intrinsic in-game advertising platform to measure in-game advertising campaigns using Comscore Campaign Ratings, Comscore's flagship solution for modern cross-platform media measurement. "Anzu's selection of Comscore Campaign Ratings enables us to validate the reach of our audiences and showcase the incrementality of that reach against other channels on behalf of brands," said Itamar Benedy, CEO and Co-Founder, Anzu. "The effort marks a significant milestone in our long-standing partnership, with Comscore's ability to provide a broad view across platforms and environments proving extremely valuable to us and our advertiser partners."

08:15 EDT Candel Therapeutics to join Russell 3000 Index - Candel Therapeutics announced that the Company is set to join the broad-market Russell 3000 Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024.

08:14 EDT Crown Castle announces plans to enhance operational performance - Crown Castle announced plans to enhance operational performance. "As we have continued to progress the strategic and operating review of Crown Castle's fiber business, we are implementing changes designed to drive operational efficiencies and to enhance returns in fiber solutions and small cells. These changes are being implemented, regardless of the outcome of the strategic review, which remains active and ongoing," stated Steven Moskowitz, Crown Castle's President and Chief Executive Officer. "With these changes, we are pursuing a more focused sales effort to target on-net and near-net demand and, critically, increasing return thresholds on all new growth opportunities to drive a more efficient use of capital. We believe implementing these changes will lower our capital expenditures on lower-return opportunities in 2024 by $275 million to $325 million while maintaining our expectations for revenue growth across towers, small cells, and fiber solutions over the next several years. Because this reduction in capital expenditures leads to reduced activity, we are also reducing staffing levels and closing certain offices, which we expect will drive approximately $100 million of annualized run-rate operating cost savings, significantly improving our ability to convert incremental revenue into cash flow. We believe this increased focus on cost discipline and capital efficiency will enable us to generate higher returns and reduce our reliance on external capital to fund organic growth opportunities."

08:11 EDT Charles River in collaboration with MatTek awarded $1.3M grant from FCRI - Charles River Laboratories International announced a multidisciplinary program, funded through a $1.3M grant from the Foundation for Chemistry Research & Initiatives FCRI, in coordination with the American Chemistry Council's Long-Range Research Initiativ ACC LRI , to develop a New Approach Methodology NAM inhalation toxicology test to reduce reliance on traditional animal research methods. The program is a collaboration between Charles River's Edinburgh, Scotland team, along with MatTek Corporation (in vitro EpiAirway model and expertise), dosimetry modeling by Battelle, and modeling consultancy from Greek Creek Toxicokinetics Consulting, . This collaboration is guided by Charles River's Alternative Methods Advancement Project an initiative focused on reducing the use of animals in research. "We are deeply committed to advancing alternative methods, and this program is an important step toward removing the need for animal models in inhalation toxicology studies," said Shannon Parisotto, Corporate Executive Vice President, Global Discovery & Safety Assessment. "Charles River's industry-leading expertise uniquely positions us to progress research in this area, and we are excited by the multidisciplinary

08:10 EDT Trio Petroleum completes first two exploratory wells in Utah - Trio Petroleum Corp provided updates on its recently completed drilling activities in Uintah County, Utah. The Company has successfully drilled its first two exploratory wells, the HSO 8-4 and HSO 2-4. The HSO 8-4 was drilled to a total depth of 1,020', while the HSO 2-4 was drilled to a depth of 1,390'. The wells encountered substantial oil-bearing pay zones in the Rimrock and Asphalt Ridge Sandstones, over 100' of oil-pay in the Rimrock Sandstone in the HSO 8-4 well and over 190' combined in the Rimrock and Asphhalt Ridge Sandstones in the HSO 2-4 well.

08:09 EDT Velo3D announces 1-for-35 reverse stock split - Velo3D announced that its board of directors has approved a 1-for-35 reverse stock split of the company's common stock. The common stock will open for trading on the NYSE on Thursday, June 13, on a split-adjusted basis under the current trading symbol. The reverse stock split is intended to enable Velo3D to regain compliance with the minimum share price required for continued listing on NYSE. The reverse stock split was approved by Velo3D's stockholders on June 10 with the final ratio determined by the company's board of directors on June 10. The company will file an amendment to its certificate of incorporation with the Secretary of State of Delaware on June 12. The reverse stock split will not reduce the number of authorized shares of the company's common stock, which will remain at 500,000,000, and will not change the par value of the common stock, which will remain at $0.00001 per share. The 1-for-35 reverse stock split will automatically convert 35 current shares of Velo3D's common stock into one new share of common stock.

08:08 EDT electroCore to join Russell Microcap Index - electroCore announced that its stock is on the preliminary additions list for inclusion in the Russell Microcap Index after its 2024 annual reconstitution. The newly reconstituted indexes will take effect after the market close on June 28, 2024, with the newly effective reconstituted family of indices beginning trading after the open of trading on July 1, 2024, according to a preliminary list of additions posted by FTSE Russell on May 24, 2024.

08:07 EDT Envoy Medical appoints Michael Crowe to board of directors - Envoy Medical (COCH) announced the appointment of Michael Crowe to the Envoy Medical Board of Directors effective June 7, 2024. Envoy Medical is currently sponsoring an Early Feasibility Study at Mayo Clinic in Rochester, Minnesota for its investigational fully implanted Acclaim Cochlear Implant. Envoy Medical expects to begin a larger pivotal clinical study for its device later in 2024. Crowe is currently the Senior Vice President of Operations for Bioventus (BVS). Mr. Crowe will qualify as an Independent Director and serve on the Compensation Committee.

08:06 EDT NewAmsterdam Pharma announces USPTO issued patent for Obicetrapib - NewAmsterdam Pharma Company announced that the United States Patent and Trademark Office, USPTO, has issued U.S. Patent No. 12,006,305, titled "Salts of Obicetrapib and Processes for their Manufacture and Intermediates Thereof." "We are excited to announce that obicetrapib has been granted our third-generation composition of matter patent by the USPTO, which extends obicetrapib's IP protection and exclusivity until July 2043, more than 9 years beyond our previous second-generation patent expiration in 2034," said Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam. "There continues to be a need for a safe, efficacious, oral, and potent LDL-lowering therapy. Securing robust patent protection for obicetrapib enables us both to continue the execution of multiple ongoing pivotal Phase 3 trials, as well as reap the potential benefits of obicetrapib's scientific innovation years beyond potential FDA approval."

08:05 EDT Predictive Oncology develops technology designed to express GPCRs - Predictive Oncology announced the introduction of a new technology designed to express functional and stable G-Protein Coupled Receptors. GPCRs are cell surface membrane receptors that are believed to play a key role in tumorigenesis, with prior studies demonstrating involvement in cancer initiation, progression, and metastasis. It is estimated that drugs targeting GPCRs represent more than 30% of the global market for therapeutic drugs, yet the number of characterized GPCR targets represent just a small fraction of the GPCR superfamily, suggesting significant potential to further target GPCRs for future drug discovery and development. Predictive Oncology plans to combine this proprietary GPCR expression system with its current High-Throughput Self-Interaction Chromatography protein solubilization technology to enable the rapid identification of solution conditions that maintain purified GPCRs in a soluble and stable form. The company believes this can overcome many of the difficulties seen with existing expression technologies.

08:04 EDT Genius Group launches Abu Dhabi, Dubai Genius Cities, AI Hubs - Genius Group Limited announced the launch of two Genius Cities in Dubai and Abu Dhabi, United Arab Emirates, with a first AI Ready Workshop taking place June 25, 2024 at Abu Dhabi University. The Genius City model gives schools, startups, corporations and government localized and personalized AI powered training, case studies and a marketplace of AI talent and solutions. This enables forward-thinking cities - such as Dubai and Abu Dhabi - to be world leaders with their own Sovereign AI.

08:02 EDT Tiziana Life Sciences receives Fast Track Designation for treatment of na-SPMS - Tiziana Life Sciences announced it has received acceptance of its submission for intranasal foralumab to receive Fast Track Designation approval for the treatment of non-active, secondary-progressive multiple sclerosis, na-SPMS, to the U.S. Food and Drug Administration, FDA. "Fast track is designed to expedite the review of drugs in development to treat serious conditions for which there are limited or no therapies," commented Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences. "The progressive nature of na-SPMS and lack of FDA-approved therapies for this disease aligns with the Food and Drug Administration's criteria for Fast Track Designation. The increased interaction and partnership with the FDA afforded by this designation would be a tremendous asset to our foralumab development program, if granted," he added.

08:01 EDT 60 Degrees Pharmaceuticals receives FDA ODD for Tafenoquine - 60 Degrees Pharmaceuticals announced that the U.S. Food and Drug Administration has granted its investigational tafenoquine candidate orphan drug designation, ODD, for the treatment of patients with acute babesiosis. "Results of recent animal studies of tafenoquine show exciting promise for the drug to have potential in human patients with acute babesiosis," said Chief Executive Officer of 60 Degrees Pharmaceuticals, Geoff Dow, PhD. "The FDA granting tafenoquine orphan drug designation for acute babesiosis validates the growing need for an additional therapeutic option that infectious disease specialists can use in addressing this very serious, potentially life-threatening illness. We look forward to results of our clinical trial program in coming months and to the prospect of securing a secondary indication for tafenoquine in the area of acute babesiosis treatment."

08:01 EDT Lowe's promotes Jennifer Wilson to Chief Marketing Officer - Lowe's promoted Jennifer Wilson to SVP, Chief Marketing Officer, effective June 10. Wilson joined Lowe's in 2006 and most recently served as senior vice president, enterprise brand and marketing. She has held multiple leadership roles with Lowe's, including vice president, integrated marketing, and merchandising vice president, paint. Before joining Lowe's, she held various leadership roles at advertising and marketing agencies.

07:51 EDT Fairfax Financial terminates total return swaps of Ensign Energy Services - Fairfax Financial Holdings (FRFHF) announces that on June 10, 2024, it terminated total return swaps over 7,787,600 common shares of Ensign Energy Services Inc. (ESVIF), which had an average reference price of C$1.3182. Upon the termination of the total return swaps, Fairfax agreed with the counterparty to purchase 7,787,600 Common Shares at a price of C$2.34 per Common Share, representing 4.24% of the outstanding Common Shares. Prior to the acquisition of the Common Shares, Fairfax beneficially owned and controlled 21,800,886 of the issued and outstanding Common Shares, representing approximately 11.86% of all issued and outstanding Common Shares. Following the acquisition of the Common Shares, Fairfax beneficially owns and controls 29,588,486 of the issued and outstanding Common Shares, representing approximately 16.10% of all issued and outstanding Common Shares and no longer is a party to any swap contracts in respect of Common Shares.

07:43 EDT Barnes & Noble Education to effect 1-for-100 reverse stock split - The board of directors will effectuate a reverse stock split of the company's outstanding shares of common stock at a ratio of 1-for-100, which was previously approved by stockholders at a special meeting held on June 5. The reverse stock split will become effective at 5:01 p.m. Eastern Time on Tuesday, June 11 and the company's shares of common stock will begin trading on the NYSE on a reverse split-adjusted basis when the NYSE opens on Wednesday, June 12. In connection with the reverse stock split, every 100 shares of the company's common stock issued and outstanding as of the effective time will be automatically converted into one share of the company's common stock. No change will be made to the trading symbol for the company's shares of Common Stock, "BNED," in connection with the reverse stock split. The reverse stock split is part of the company's plan to regain compliance with the minimum bid price requirement of $1.00 per share required to maintain continued listing on the NYSE. The reverse stock split will reduce the number of shares of the company's outstanding common stock from approximately 2,620.5 shares to approximately 26.2M shares, subject to adjustment for rounding.

07:36 EDT Allegion acquires Canada- based Unicel Architectural, terms undisclosed - Allegion, through one of its subsidiaries, has acquired Unicel Architectural or Unicel Architectural . Based in Quebec, Canada, Unicel Architectural is a leading North American manufacturer of advanced glass, timber and aluminum building solutions that support privacy, safety, energy efficiency and sustainability. The Unicel Architectural portfolio is primarily sold across Canada and the U.S. and installed in healthcare, education, government and other non-residential facilities. Unicel Architectural will operate as part of the Allegion Americas segment, led by Allegion Senior Vice President Dave Ilardi. "Unicel Architectural is a natural extension of Allegion's core business, especially in institutional markets. This strategic combination will strengthen our portfolio of solutions and expand our specification capabilities," Ilardi said. "Together, we will provide meaningful differentiation for customers with more comprehensive offerings." Unicel Architectural Co-Presidents Samuel Doyon-Bissonnette and Vincent Couturier are joining Allegion and will serve as leaders for Unicel Architectural within the Allegion Americas non-residential business, supporting a smooth transition and helping drive accelerated growth. Terms of the transaction were not disclosed.

07:35 EDT Net Lease Office sells two office properties for $61M - Net Lease Office announced the sale of two office properties leased to Blue Cross Blue Shield for gross proceeds totaling $60.7M. Net proceeds after closing costs were used to repay approximately $48M on J.P. Morgan's senior secured mortgage and approximately $8M on its mezzanine loan. This resulted in outstanding balances of approximately $151M and $92M, respectively, as of June 10. Following the sale, NLOP owned 47 office properties, comprising 44 properties in the U.S., including three remaining properties leased to Blue Cross Blue Shield, and three properties in Europe.

07:33 EDT Sonder Holdings announces amendment to financing agreement - Sonder Holdings has entered into an amendment to its existing note and warrant purchase agreement with a syndicate of investors, which provides for, among other things, additional commitments with an aggregate principal amount of $10M which will improve the Company's unrestricted liquidity.

07:32 EDT Zimmer Biomet signs agreement with THINK Surgical for robotic solution - Zimmer Biomet announced a limited distribution agreement with THINK Surgical regarding its wireless, handheld, TMINI Miniature Robotic System for total knee arthroplasty. The agreement will result in an exclusive offering, integrating Zimmer Biomet technology into a customized TMINI robotic solution. The TMINI system complements Zimmer Biomet's flagship ROSA Robotics portfolio with a handheld robotic option that enables accurate implant placement to a predetermined CT-based, three-dimensional surgical plan. Zimmer Biomet anticipates introducing the customized TMINI System to select markets in the U.S. in the second half of 2024.

07:31 EDT Monopar Therapeutics, NorthStar Medical amend, extend collaboration - Monopar Therapeutics and NorthStar Medical Radioisotopes announced an amendment and expansion to their existing collaboration. Under terms of the revised collaboration, the Companies entered into a long-term, non-exclusive master supply agreement for NorthStar to provide Monopar with the powerful therapeutic radioisotope actinium-225. The amendment builds on NorthStar's significant investment in Ac-225 manufacturing and Monopar's promising preclinical therapeutic results with Ac-225 in its lead MNPR-101 radiopharma program. The amendment also clarifies certain economic terms and those related to jointly developed intellectual property rights for Monopar's MNPR-101 for radiopharmaceutical use. Monopar has acquired those rights from NorthStar, together with certain broad, jointly developed intellectual property pertaining to MNPR-101, giving Monopar full ownership and title to its lead MNPR-101 radiopharmaceutical platform. Both companies will share ownership of the filed patent application on the use of PCTA as a linker with Ac-225, which has shown superior binding and yield with Ac-225 over the current industry-leading linker, DOTA.

07:15 EDT Recruiter.com granted continued listing from Nasdaq Hearings Panel - Recruiter.com Group received a notification letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market that the Company has evidenced full compliance with all requirements for continued listing on The Nasdaq Capital Market, including the minimum stockholders' equity requirements set forth in Nasdaq Listing Rule 5550(b)(1). On August 17, 2023, the Staff notified the Company that it was not in compliance with the Minimum Stockholders' Equity Requirement because its stockholders' equity as reported in its Quarterly Report on Form 10-Q for the period ended June 30, 2023 was not at least $2,500,000 and the Company did not currently meet the alternatives of market value of listed securities or net income from continuing operations. The Staff granted the Company's request for an extension until February 13, 2024, to comply with this requirement. However, the Company failed to meet the terms of the extension, and on February 16, 2024, Staff sent a Delist Determination. On February 21, 2024, the Company submitted a hearing request to Nasdaq's Hearings Department. The hearing request stayed the delisting of the Company's securities pending the panel's conclusion of the hearing process. The hearing was held on April 18, 2024, and by decision dated May 9, 2024, the Panel granted the Company an extension to evidence compliance with all applicable continued listing criteria, through May 20, 2024. As stated above, the Hearings Panel was satisfied with the Company's compliance. The Company remains subject to a "Panel Monitor" as that term is defined under Nasdaq Listing Rule 5815(d)(4)(A), through June 6, 2025. "We are grateful for the opportunity from Nasdaq to continue to implement our growth and recapitalization plan," said Granger Whitelaw, Chief Executive Officer of Recruiter.com Group, Inc. "Recruiter has made significant progress on our plan to reduce debt, raise equity, improve operational efficiencies and drive growth through acquisition. The solidification of our continued listing position will greatly assist in those plans." The Company has engaged in preliminary negotiations and due diligence with several private operating companies for the purpose of acquiring revenue-generating operating assets or businesses that are synergistic with the Company's business plan and model. Any such acquisitions would be consummated in conjunction with one or more private or public placements of Company securities to help facilitate such acquisitions. The Company is in discussions with certain strategic investors to issue up to $6.5 million of shares of the Company's common stock in a private transaction, the proceeds of which would be to further the Company's acquisition strategy. No material agreements, binding or otherwise, have been executed to date with either acquisition targets or potential new investors. Such funding could also be used for working capital and other general corporate purposes, including completing the Company's planned spinout of certain operating assets and liabilities to its Atlantic Energy Solutions, Inc. subsidiary, which is currently being renamed CognoGroup, Inc.

07:11 EDT Aclara Resources submits new EIA for Penco Module - Aclara Resources has filed a new Environmental Impact Assessment for the Penco Module project with the Environmental Service Assessment in Concepcion, Chile. The EIA incorporates an improved technical design of the Project, which the Company believes addresses all concerns related to environmental and social requirements from the public services and local communities. In addition, the EIA has further been optimized following the review conducted by CAP. As Aclara's strategic partner in Chile, the Company will continue to leverage CAP's expertise and support through the course of its permitting process. Highlights: Building on the new technical design of the Project and local community feedback, the EIA includes the following highlights: Commitment to protecting native forests: New Project design excludes the Jupiter deposition zone and modifies other components to avoid the areas where the 6 "naranjillo" trees were previously found; Revegetation of over 100 hectares with native species; "Early Citizen Participation" process aimed at co-designing the Project with the Penco community, reflecting greater involvement of its residents: Held meetings with over 1,000 residents, leaders, and opinion leaders of Penco; Received 303 recommendations and comments from the local community reflecting a greater degree on integration of the community as stakeholders; Conducted over 400 guided tours to the Company's pilot plant for residents of the Penco community and academic researchers, who verified the environmental-friendly attributes and sustainability features of the Company's circular mineral harvesting process; Established the Aclara house near Penco's main square as a dedicated space for ongoing dialogue with the community. Each week, approximately 100 Penco residents visit Casa Aclara to receive information about the Project directly from the Company; Commitment to source 100% of the estimated water requirements of the Project with recycled water; Addressed the observations received from the evaluation services in relation to the previous EIA.

07:10 EDT General Motors board approves new $6B share repurchase plan

07:09 EDT NFI Group's Alexander Dennis announces contract with Reading Buses - NFI Group subsidiary Alexander Dennis Limited announced that it has confirmed new orders for 24 zero-emission and 29 low-emission buses for English bus operator Reading Buses. The 24 next-generation Alexander Dennis Enviro400EV double deckers will be the operator's first batch of electric buses. They are the result of a successful bid with Reading Borough Council for funding from the second round of the UK Government's Zero-Emission Regional Bus Areas scheme.

07:08 EDT Perspective Therapeutics announces 1-for-10 reverse stock split - Perspective Therapeutics announced that it will effect a 1-for-10 reverse stock split effective on June 14, 2024. Beginning with the opening of trading on June 17, 2024, Perspective's common stock is expected to begin trading on the NYSE American on a split-adjusted basis under the existing trading symbol "CATX."

07:05 EDT Kaltura announces stock repurchase program for up to $5M - Kaltura announced that its Board of Directors has authorized a stock repurchase program for up to $5 million of the Company's common stock. "This repurchase authorization underscores the Board and Management's strong conviction that our current share price is undervalued relative to our long-term opportunity. We remain committed to strategically deploying capital where we believe it can generate shareholder value," said Ron Yekutiel, Chairman, President and Chief Executive Officer.

07:04 EDT Orthofix names Julie Dewey Chief Investor Relations and Communications Officer - Orthofix Medica announced the appointment of Julie Dewey as Chief Investor Relations and Communications Officer. Additionally, as previously announced, Max Reinhardt begins as President of the company's global spine business. Dewey and Reinhardt will serve on Orthofix's Executive Leadership Team. A seasoned investor relations and communications executive, Dewey previously held roles as a corporate officer for multiple global publicly traded medical device companies. Most recently, she served as Chief Communications and Investor Relations Officer for Treace Medical Concepts, Inc., a medical technology company focused on the surgical management of bunion and related midfoot deformities. Earlier in her career, she was the Senior Vice President and Chief Communications Officer at Wright Medical Group, a global medical device company focused on extremities and biologics that was acquired by Stryker in 2020.

07:03 EDT Lithium Ionic completes acquisition of remaining 15% of Salinas properties - Lithium Ionic reports that, further to its May 30, 2024 press release, its wholly owned subsidiary, Neolit Minerals Participacoes Ltda, has completed the acquisition of the remaining 15% of select Salinas properties, located within the Curralinho Pegmatite Field of the lithium-rich Aracuai Pegmatite District, in Minas Gerais, Brazil. Lithium Ionic now owns 100% of the Salinas group of properties. As consideration pursuant to the Transaction, the Company has paid the vendor: A cash payment of the Brazilian Real equivalent of $2 million; The issuance of 2.5 million shares of Lithium Ionic. Additionally, the Company is required to make a subsequent payment of the Brazilian Real equivalent of $1 million by April 4, 2025. Please refer to the Company's May 30, 2024 press release for further details regarding the Transaction. A Preliminary Economic Assessment for Salinas is currently being conducted by the independent Brazilian consultancy, GE21 Consultoria Mineral Ltda, based in Belo Horizonte, Minas Gerais, and is expected to be completed in the second half of 2024. The Transaction is an arm's-length transaction, and no finder's fees were paid in connection with it.

07:03 EDT PepGen promotes Michelle Mellion to chief medical officer - PepGen announced two executive team promotions effective immediately: Michelle Mellion to chief medical officer and Hayley Parker to senior VP, global regulatory affairs.

07:02 EDT Regeneron, Sanofi announce FDA approved Kevzara for treatment of pJIA - Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. Food and Drug Administration has approved Kevzara for the treatment of patients weighing 63 kg or greater with active polyarticular juvenile idiopathic arthritis, pJIA,, a form of arthritis that impacts multiple joints at a time. "Polyarticular juvenile idiopathic arthritis can be a painful disease for children where multiple joints are impacted by this chronic infammation," said George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer at Regeneron. "Not only are their daily lives impacted, but their futures can be disrupted without adequate treatment. The approval of Kevzara in polyarticular juvenile idiopathic arthritis provides these vulnerable patients and their families a new FDA-approved treatment option to help navigate this disease."

06:47 EDT Chemours receives approval of science-based emissions reduction targets - The Chemours Company announced that the Science Based Target initiative has approved Chemours' near-term science-based greenhouse gas emissions reduction targets. This includes the company's existing goal of an absolute 60% reduction in Scope 1 and 2 GHG emissions by 2030 and a new Scope 3 target to reduce emissions by 25% per ton of production by 2030.

06:47 EDT Kennametal resumes operations at Arkansas facility - Kennametal announced that it has resumed operations at its facility in Rogers, Arkansas, following a previous shutdown due to damage from a tornado on May 26. "The restart of our Rogers facility is a testament to the great teamwork of our local team and the tremendous support and coordination of expert resources across the entire organization," said Sanjay Chowbey, President and CEO of Kennametal Inc. "Our team worked around the clock to ensure operations could resume safely and we continue to take important steps forward every day to meet customers' expectations." The company continues to assess the financial effects of the storm and is working with its insurance carrier. As previously announced, the facility was shut down for the Memorial Day weekend when the tornado struck, and no one was injured. The Rogers plant supports the company's Infrastructure segment and produces engineered carbide wear components primarily serving the Energy, General Engineering and Earthworks end markets. The facility also produces rods used in the manufacturing of certain round tools for the Company's Metal Cutting segment.

06:35 EDT Clean Energy expands Boron, California, LNG Plant capacity by 50% - Clean Energy announced that construction of a third production train at its liquefied natural gas plant in Boron, California, has been completed, increasing the plant's volume capacity by 50%. The Boron plant now has the capacity to produce up to 270,000 gallons of cleaner-burning LNG every day. The addition of the third production train will allow the supply to meet the growing demand for bulk LNG by customers looking to decarbonize everything from city buses to large container ships.

06:32 EDT BJ's Wholesale expands same-day delivery service to include big-ticket items - BJ's Wholesale Club announced an expansion of its popular same-day delivery service to include big-ticket items. BJ's members in participating ZIP codes are able to order items like patio sets, grills and televisions for delivery, made possible through collaboration with Roadie, a UPS company.

06:26 EDT Target Hospitality sinks with U.S. closing South Texas immigrant facility - Shares of Target Hospitality are sinking after the company confirmed that the U.S. government intends to terminate the existing South Texas Family Residential Center services agreement with Target's migrant programming partner, effective in 60 days, or on or about August 9. Target provides facility and hospitality solutions to the immigrant facility through a lease and services agreement. Shares of Target Hospitality are down 28%, or $2.94, to $7.56 in premarket trading.

06:03 EDT Viridian Therapeutics updates VRDN-003 Phase 3 program in thyroid eye disease - Viridian Therapeutics reported details of its plans to initiate a phase 3 clinical trial program for its SC VRDN-003 product candidate for patients with moderate-to-severe thyroid eye disease, or TED. Viridian is planning to initiate two phase 3 clinical trials designed to evaluate the efficacy and safety of subcutaneously administered VRDN-003 in patients with active and chronic TED, named REVEAL-1 and REVEAL-2, respectively. These clinical trials are expected to initiate in August. The primary endpoint in each clinical trial will be proptosis responder rate, based on the achievement of at least 2mm improvement in proptosis from baseline at week 24, versus placebo. Viridian anticipates topline data for both clinical trials to be available in the first half of 2026 and to file a BLA by the end of 2026. The company plans to launch VRDN-003 with a commercially available autoinjector pen.

05:36 EDT Rocket Lab signs PMT with Department of Commerce for $23.9M in direct funding - Rocket Lab announced the signing of a non-binding preliminary memorandum of terms, or PMT, with the Department of Commerce that would see Rocket Lab receive up to $23.9M in direct funding under the CHIPS and Science Act. The proposed investment would enable Rocket Lab to increase its production of compound semiconductors for spacecraft and satellites, as part of an expansion and modernization of the Company's facility in Albuquerque, New Mexico. This proposed CHIPS investment would create more than 100 direct manufacturing jobs. The modernization and expansion project would also increase Rocket Lab's compound semiconductor production by 50% within the next three years-helping to domestically meet the growing national security and consumer demand for these solar cells. In addition to these proposed federal incentives, the State of New Mexico has also committed to providing financial assistance and incentives with a total value of $25.5 million to Rocket Lab in support of this effort.

05:30 EDT Molecular Partners, Orano Med present MP0712 data at SNMMI - Molecular Partners and Orano Med announced the debut of their lead Radio-DARPin therapy, or RDT, candidate MP0712, targeting DLL3, in an oral presentation. The data presented provide support for MP0712's clinical development in small-cell lung cancer, or SCLC, and other DLL3+ neuroendocrine tumors. MP0712 features 212Pb as a potent therapeutic payload. The data were presented at the Society of Nuclear Medicine and Molecular Imaging, or SNMMI, 2024 annual meeting taking place June 8-11 in Toronto, Canada. MP0712 is the first high-affinity DLL3-targeting RDT combining the advantages of DARPins as small protein-based delivery vectors and the short-lived alpha particle-emitting radioisotope 212Pb. DLL3 is expressed in greater than 85% of SCLC patients and in other neuroendocrine tumors, while its expression in healthy tissues is low, making it a priority target for radiopharmaceutical therapy. SCLC is an aggressive form of lung cancer, with a poor five-year survival prognosis and a high unmet need for patients. The preclinical package presented at SNMMI includes in vivo data demonstrating strong and homogeneous tumor uptake of 212Pb-DLL3 RDT, as well as significant and durable inhibition of tumor growth at clinically-relevant doses. The safety results seen across the tested dosing levels in mice suggest a favorable safety profile and potential for clinical use. 212Pb-DLL3 RDT candidates were engineered by tuning their biophysical properties to achieve an optimal safety/antitumor activity profile in vivo. The selected lead candidate, MP0712, demonstrated a biodistribution profile in mouse xenograft tumor models, with close to 60% of injected dose detectable in the tumor and encouraging tumor to kidney ratios over two. The replicable DARPin learnings from the development of MP0712, as well as additional platform improvements, are being taken forward to the broader RDT portfolio. The intrinsic properties of DARPins, such as small size, high affinity and selectivity, and a broad range of potential targets, make them ideal vector candidates for radiopharmaceutical therapeutics. Historically, small protein-based vectors faced challenges with kidney accumulation and toxicity, as well as suboptimal tumor uptake. Molecular Partners has evolved its RDT platform to address these limitations with its half-life extension technologies and surface engineering approaches, while preserving the advantages of the small protein format. In addition, Molecular Partners' DARPin candidates have been clinically validated with over 2500 patients treated worldwide and multiple DARPin mechanisms have been demonstrated as biologically active in for different indications, contributing to validation of the drug class and Molecular Partners in the field of DARPin engineering and development.

05:21 EDT Arrow Electronics, Bourns collaborate to accelerate electrification - Arrow Electronics and Bourns, Inc. announced their strategic collaboration to assist customers in the development of high-power solutions, a component in advancing electrification and sustainability initiatives. High-power designs require an extensive amount of customized magnetic components from a knowledgeable supplier experienced in developing solutions for high-frequency applications. Arrow, as part of this collaboration, will leverage Bourns' expertise in customized magnetic development.

05:16 EDT ASE Technology reports May revenue $1.47M vs. $1.51M last year - Reports May ATM revenue $821M vs. $856M last year.

05:12 EDT HP Enterprise, FC Barcelona sign partnership agreement - FC Barcelona and HP Enterprise have signed a partnership agreement for HPE to become the new Espai Barca Official Edge-to-Cloud Partner for the next four seasons, until June 30, 2028. In a strategic alliance aimed at revolutionizing the spectator experience in sport, Barca's new facilities will be equipped with a technology environment featuring HPE Aruba Networking and HPE GreenLake cloud, enabling real-time data analytics and integrated security solutions. The partnership between the Club and HPE is based on an approach to edge connectivity and cloud technology, which will enable the entire Espai Barca to offer personalized services and experiences tailored to its fans.

05:06 EDT Owlet announces UK, European launch of Dream Sock - Owlet announced the UK and European launch of Dream Sock, a smart baby monitor with live health readings and notifications for healthy infants between 0-18 months and 2.5-13.6 kg. This innovative medical device provides parents with real-time health and vital information, offering unparalleled peace of mind.